Previous 10 | Next 10 |
HIGHLANDS RANCH, Colo., April 28, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities ...
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snorin...
HIGHLANDS RANCH, Colo., April 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (NASDAQ: VVOS) (“Vivos'' or the “Company''), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients with...
Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea ("OSA") and snoring in adults, is ...
Start Time: 17:00 End Time: 17:48 Vivos Therapeutics, Inc. (VVOS) Q4 2021 Earnings Conference Call March 31, 2022, 17:00 PM ET Company Participants Kirk Huntsman - Chairman and CEO Brad Amman - CFO Julie Gannon - IRO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Pres...
Vivos Therapeutics press release (NASDAQ:VVOS): FY GAAP EPS of -$0.96. Revenue of $16.89M (+29.2% Y/Y). Shares -5%. Cash and cash equivalents were $24.0 million at December 31, 2021. For further details see: Vivos Therapeutics GAAP EPS of -$0.96, revenue of $16.89M
Fourth Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29% Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the...
Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring,...
HIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities ...
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snorin...
News, Short Squeeze, Breakout and More Instantly...
Vivos Therapeutics Inc. Company Name:
VVOS Stock Symbol:
NASDAQ Market:
Vivos Therapeutics Inc. Website:
LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS) , a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments f...
Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) i...
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment Sponsored by Seneca Partners, Who Will Also Provide General Management Advisory ...